TG THERAPEUTICS, INC. Deferred Income Tax Expense (Benefit)
TG THERAPEUTICS, INC. (TGTX) reported Deferred Income Tax Expense (Benefit) of $4.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-05
- TG THERAPEUTICS, INC. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $708.00K.
- TG THERAPEUTICS, INC. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $3.86M.
- TG THERAPEUTICS, INC. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $18.63M.
- TG THERAPEUTICS, INC. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was -$366.63M.
- TG THERAPEUTICS, INC. deferred income tax expense (benefit) for fiscal 2025 was -$348.00M.
- TG THERAPEUTICS, INC. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- TG THERAPEUTICS, INC. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- TG THERAPEUTICS, INC. deferred income tax expense (benefit) for fiscal 2020 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $708.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.57M 10-Q · filed 2026-08-05 | $23.20M derived: sum of 3 quarters · filed 2026-08-05 | -$343.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.86M 10-Q · filed 2026-05-06 | $22.49M derived: sum of 2 quarters · filed 2026-05-06 | -$344.14M derived: sum of 3 quarters · filed 2026-05-06 | -$344.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $18.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$348.00M derived: sum of 2 quarters · filed 2026-02-27 | -$348.00M derived: sum of 3 quarters · filed 2026-08-05 | -$348.00M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$366.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$366.63M derived: sum of 2 quarters · filed 2026-08-05 | -$366.63M 10-Q · filed 2025-11-05 | -$366.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |